Business Context and Reporting Period
Aptevo Therapeutics Inc. filed this Form 8-K on March 30, 2017, to announce financial results for the period ended December 31, 2016, and to disclose a material accounting error requiring non-reliance on previously issued financial statements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period, as these figures are contained in the attached press release (Exhibit 99.1) which is not included in the source text.
However, the filing details specific adjustments related to an accounting error:
- Intangible Assets: $41.8 million recorded in 2015 related to the acquisition of in-process research and development (IPR&D) for TRU-016.
- Deferred Tax Liability Adjustment: $15.3 million increase required in balance sheets for periods ending December 31, 2015, March 31, 2016, and June 30, 2016.
- Goodwill Adjustment: Corresponding $15.3 million increase in goodwill.
- Impact on Net Loss: The error and subsequent adjustments did not impact the Company's net loss, revenues, or stockholders' equity.
Material Changes and Restatements
The Company concluded that previously issued financial statements for the year ended December 31, 2015, and the quarters ended March 31, June 30, and September 30, 2016, should no longer be relied upon due to errors in the accounting treatment of deferred tax liabilities associated with the 2010 acquisition of IPR&D assets.
Specific restatement impacts include:
- Balance Sheet: Increases to deferred tax liabilities and goodwill by $15.3 million for the affected dates.
- Statement of Operations: For the three and nine months ended September 30, 2016, impairment expense, loss from operations, loss before income tax, and benefit from income tax were each increased by $15.3 million.
The Company does not intend to file amendments to prior SEC filings for periods through September 30, 2016, but has corrected the statements in its 2016 Form 10-K.
Outlook, Risks, and Management Commentary
Management and the audit committee have discussed the matter with the independent registered public accounting firm. The filing notes that the error was identified during the preparation of the 2016 audited financial statements. The filing explicitly states that the information provided is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the year ended December 31, 2016, in the attached press release (Exhibit 99.1).
- Confirm the impact of the $15.3 million deferred tax liability adjustment on the Company's current balance sheet and goodwill valuation.
- Review the corrected 2016 Form 10-K to ensure the restated financial data is accurately reflected.
- Assess the status of the TRU-016 program and the indefinite-lived intangible asset classification following the spin-off.